Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. EMEND TRI-PACK CAPSULE [SIN12371P]

EMEND TRI-PACK CAPSULE [SIN12371P]

Active ingredients: EMEND TRI-PACK CAPSULE

Last updated 26 October 2025

On this page

Product Info
II. INDICATIONS
IV. DOSAGE AND ADMINISTRATION
V. CONTRAINDICATIONS

Product Info

EMEND TRI-PACK CAPSULE

[SIN12371P]

Product information

Active Ingredient and Strength

APREPITANT (IN 125 MG CAPSULE) - 125 MG
APREPITANT (IN 80 MG CAPSULE) - 80 MG

Dosage Form

CAPSULE

Manufacturer and Country

ALKERMES PHARMA IRELAND LIMITED - IRELAND
PT ORGANON PHARMA INDONESIA TBK (PRIMARY AND SECONDARY PACKAGER) - INDONESIA REP OF

Registration Number

SIN12371P

Licence Holder

MSD PHARMA (SINGAPORE) PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

A04AD12

II. INDICATIONS

EMEND is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:

  • highly emetogenic cancer chemotherapy (see DOSAGE AND ADMINISTRATION)

  • moderately emetogenic cancer chemotherapy (see DOSAGE AND ADMINISTRATION).

EMEND should be given in combination with a corticosteroid and a 5-HT3 antagonist.

IV. DOSAGE AND ADMINISTRATION

EMEND (aprepitant) is available as capsules for oral administration.

EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose of EMEND is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. The package insert for the co-administered 5-HT3 antagonist must be consulted prior to initiation of treatment with EMEND.

EMEND has not been studied for the treatment of established nausea and vomiting.

EMEND I.V. 150 mg (fosaprepitant), a lyophilized prodrug of aprepitant for intravenous administration, is also available. EMEND I.V. 150 mg is available as a single dose and is administered on Day 1 only.

Recommended dosing for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy:

Emend Capsule Dosing Table 1



Recommended dosing for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:

Emend Capsule Dosing Table 2



Chronic continuous administration is not recommended.

See DRUG INTERACTIONS for additional information on the administration of EMEND with corticosteroids – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Refer to the full prescribing information for coadministered antiemetic agents.

EMEND may be taken with or without food.

No dosage adjustment is necessary based on age, gender, race or Body Mass Index (BMI).

No dosage adjustment is necessary for patients with severe renal insufficiency (creatinine clearance <30 mL/min) or for patients with end stage renal disease undergoing hemodialysis.

No dosage adjustment is necessary for patients with mild to moderate hepatic insufficiency (Child-Pugh score 5 to 9). There are no clinical data in patients with severe hepatic insufficiency (Child-Pugh score >9).

V. CONTRAINDICATIONS

EMEND is contraindicated in patients who are hypersensitive to any component of the product.

EMEND should not be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of cytochrome P450 isoenzyme 3A4 (CYP3A4) by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions (see DRUG INTERACTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).